Back to top

Image: Bigstock

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

Read MoreHide Full Article

Key Takeaways

  • Omnicell is expanding across care settings, with Titan XT and OmniSphere central to its growth plans.
  • Omnicell's recurring offerings made up 53% of third-quarter revenues, with SaaS and services at $67 million.
  • Omnicell raised 2026 adjusted EBITDA guidance to $187-$193 million and adjusted EPS to $2.48-$2.56.

Omnicell (OMCL - Free Report) is well-positioned for growth in the coming quarters, supported by expansion across care settings, growth in recurring revenues and the planned rollout of Titan XT and OmniSphere. The company is seeing growing customer engagement around its enterprise-wide medication management platform. Omnicell is also strengthening profitability through cost discipline, improved margins and higher adjusted EBITDA. Yet, rising input costs and slower-than-expected recurring-revenue expansion could weigh on its performance.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 1.1% compared with the industry’s 2.4% growth and the S&P 500 composite’s 11.5% rise.

The renowned healthcare technology company has a market capitalization of $1.56 billion. Its earnings yield of 7% favorably compares to the industry’s negative 1.2% yield. Omnicell surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average earnings surprise of 46.4%. 

Let’s delve deeper.

Tailwinds Supporting OMCL Stock

Strategic Imperatives to Drive Growth: Omnicell's first growth priority centers on broader deployment across inpatient and outpatient settings, spanning nursing units, pharmacy operations and other medication workflows. In the third quarter of 2026, management reported further XT expansion wins, including a large academic medical center in the Northeast and multistate health systems. The second priority is scaling recurring revenues from cloud-based software, subscriptions and services. Service revenues were approximately $135 million in the third quarter of 2026 versus $133 million a year earlier. SaaS and Expert Services contributed approximately $67 million, and recurring offerings represented 53% of quarterly revenues.

Zacks Investment Research
Image Source: Zacks Investment Research

The final priority is advancing OmniSphere, a cloud-native platform designed to unify Omnicell's products, improve medication visibility and support analytics. With Titan XT shipments planned for the second half of 2026 and OmniSphere's launch targeted for the first half of 2027, management sees an XT installed-base replacement opportunity exceeding $2.5 billion.

Autonomous Pharmacy Model Holds Growth Potential: Autonomous pharmacy remains a long-term opportunity for Omnicell to improve operational efficiency and reduce medication-management errors. Although labor, cost and workflow constraints can delay purchasing decisions, they also increase the need for automation, visibility and standardized processes. Omnicell has moved beyond point solutions toward an enterprise medication-management platform that connects devices, data and workflows.

In the third quarter of 2026, management described growing customer engagement around enterprise-wide medication management and a product pipeline modestly larger than at the end of the second quarter. Titan XT and OmniSphere remain central to discussions with existing users and prospective competitive conversions. Customers are evaluating reliability, clinical workflows and the benefits of linking hardware with cloud intelligence. Management also cited XT expansion wins at several health systems and continued traction in government channels.

Cost Discipline Supports Earnings Leverage: Omnicell continues to control expenses while investing in next-generation products. Adjusted EBITDA reached $45 million in the third quarter of 2026, up from $41 million a year earlier, despite the absence of the second quarter's $15 million tariff refund. Adjusted operating expenses declined 2% year over year to $108 million. Adjusted gross margin improved 120 basis points to 45.4%. Management raised full-year 2026 adjusted EBITDA guidance to $187-$193 million from $175-$185 million and adjusted EPS guidance to $2.48-$2.56 from $2.15-$2.30. A favorable sales mix and continued cost management may support profitability as the refresh cycle scales.

What Ails OMCL?

Input Cost Volatility May Strain Margins: Omnicell remains exposed to changes in component costs, supply chains and trade-related inputs. The second quarter of 2026 benefited from a one-time $15 million refund of previously paid tariffs, which boosted product gross margin and earnings. That benefit did not recur in the third quarter.

The company continues to face an imbalanced market for memory chips, with about $6 million of incremental costs expected in the second half of 2026. Management said roughly half of that increase occurred in the third quarter and the remainder was expected in the fourth. It estimates that the memory-cost increase will reduce full-year 2026 adjusted EBITDA and adjusted EPS guidance by about $6 million and 9 cents, respectively.

Recurring Revenue Transition Is Taking Longer Than Expected: The recurring-revenue strategy remains attractive, but the pace of expansion is uncertain. Omnicell narrowed its year-end 2026 annual recurring revenue guidance to $660-$670 million from $660-$680 million after the third quarter, reducing the midpoint. Management attributed the weaker trajectory mainly to slower development of consumables opportunities, with 340B policy changes as another potential drag. 

OMCL Stock Estimate Trend

The Zacks Consensus Estimate for OMCL’s 2026 earnings per share (EPS) has jumped 11.2% to $2.39 in the past 30 days. 

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $1.23 billion. This suggests a 4% increase from the year-ago reported number.

Key Picks

Some better-ranked stocks in the broader medical space are Bausch + Lomb Corp. (BLCO - Free Report) , Insulet (PODD - Free Report) and IDEXX Laboratories (IDXX - Free Report) .

Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 43.3% compared with the industry’s 9.9% rise over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%. 

BLCO sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4% compared with the industry’s 9.3% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 59.6% compared with the industry’s 20.7% decline over the past year.

IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have risen 0.2% compared with the industry’s 2.4% gain over the past year.

Published in